本帖最后由 老马 于 2013-3-13 13:43 编辑
3 C; e7 g- |! V4 u2 k# u: J0 U/ B' x; h; f$ ^
健择（吉西他滨）+顺铂+阿瓦斯汀. n" z4 a; H4 b% K9 { M& X
Gemzar +Cisplatin + Avastin
' g9 a5 m' A. ?: f9 I6 ehttp://annonc.oxfordjournals.org/content/21/9/1804.full* j! ?7 @! T3 j6 ^8 n
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 0 o& e! d+ d9 d( O
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 m" E/ ^( w( WResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 9 l' M6 \4 c7 q' \1 v
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1140)
. f) U5 t* H& L: n8 C0 j4 f' @2 O S$ b" A华为网盘附件：! m2 u8 t/ M& Q# X9 ~& |6 i
【华为网盘】ava.JPG
% [3 z( [$ ?' z9 @; { |
11011102001537 )
显身卡
